TPX-0005
- CAS No.
- 1802220-02-5
- Chemical Name:
- TPX-0005
- Synonyms
- Repotrectinib;TPX-005;Ropotrectinib;CS-2479;TPX-0005;Loprotinib;PX0005(Ropotrectinib);Ropotrectinib(TPX0005);TPX0005(Ropotrectinib);TPX-0005,Repotrectinib
- CBNumber:
- CB83312797
- Molecular Formula:
- C18H18FN5O2
- Molecular Weight:
- 355.37
- MOL File:
- 1802220-02-5.mol
- Modify Date:
- 2024/7/2 8:55:27
| Density | 1.46±0.1 g/cm3(Predicted) |
|---|---|
| storage temp. | Store at -20°C |
| solubility |
DMSO:35.0(Max Conc. mg/mL);98.5(Max Conc. mM) Ethanol:10.0(Max Conc. mg/mL);28.1(Max Conc. mM) |
| form | A crystalline solid |
| pka | 10.79±0.60(Predicted) |
| color | White to off-white |
| InChI | InChI=1S/C18H18FN5O2/c1-10-8-20-18(25)14-9-21-24-6-5-16(23-17(14)24)22-11(2)13-7-12(19)3-4-15(13)26-10/h3-7,9-11H,8H2,1-2H3,(H,20,25)(H,22,23)/t10-,11+/m0/s1 |
| InChIKey | FIKPXCOQUIZNHB-WDEREUQCSA-N |
| SMILES | O1C2=CC=C(F)C=C2[C@@H](C)NC2C=CN3C(N=2)=C(C=N3)C(=O)NC[C@@H]1C |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P305+P351+P338 | |||||||||
| NFPA 704 |
|
TPX-0005 Chemical Properties,Uses,Production
Description
Ropotrectinib (TPX-0005; TP Therapeutics, San Diego, CA, USA) is a nextgeneration ROS1 inhibitor, a novel three-dimensional macrocyle with a much smaller size (MW <370) than current ROS1 inhibitors. It was specifically designed to overcome resistance mutations. Preclinical studies have shown activity against gatekeeper and solvent mutations, including G2032R, D2033N, L2026M, S1986F/Y, L1951R, and kinases involved in bypass signaling such as focal adhesion kinase, SRC proto-oncogene, and non-receptor tyrosine kinase [102, 103].
Description
Repotrectinib, also known as TPX-0005, is a multikinase (ROS1, ALK, and TRKA/B/C) inhibitor that is tested in an ongoing first-in-human phase 1/2 trail (NCT03093116).
General Description
Class: receptor tyrosine kinase; Treatment: NSCLC; Other name: TPX-0005
Biological Activity
Repotrectinib is a potent inhibitor targeting solvent-front mutations (SFMs) of ROS1, pan-TRK, and ALK. It effectively inhibits the kinase activity of wild-type ROS1, TRKA-C, and ALK, along with their SFMs, with IC50 values ranging from 0.071 to 4.46 nM. The compound shows high potency against ROS1 and TRKA-C, with approximately 15-fold selectivity over ALK.
Clinical Use
Repotrectinib has advantage with central nervous system (CNS) penetration, aimed to target both wide-type (WT) and solvent-front mutations (SFM) kinases and other resistance mutations including ROS1-G2032R and ROS1-D2033N, TRKA-G595R, TRKB-G639R, TRKC-G623R, and ALK-G1202R.
target
Primary targets: NTRK, ROS, ALT
TPX-0005 Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Zhengzhou Anhuida Chemical Co., Ltd | +8615903659408 | China | 297 | 58 | Inquiry |
| Jinan Million Pharmaceutical Co., Ltd | 0531-68659554 +8613031714605 | China | 213 | 58 | Inquiry |
| Hebei Yanxi Chemical Co., Ltd. | +8617531190177 | China | 5873 | 58 | Inquiry |
| Henan Tianfu Chemical Co.,Ltd. | +86-0371-55170693 +86-19937530512 | China | 21662 | 55 | Inquiry |
| BOC Sciences | +1-631-485-4226 | United States | 19553 | 58 | Inquiry |
| Zhengzhou Alfa Chemical Co.,Ltd | +8618530059196 | China | 13484 | 58 | Inquiry |
| ANHUI WITOP BIOTECH CO., LTD | +8615255079626 | China | 23555 | 58 | Inquiry |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 | China | 10522 | 58 | Inquiry |
| InvivoChem | +1-708-310-1919 +1-13798911105 | United States | 6393 | 58 | Inquiry |
| Nanjing Doge Biomedical Technology Co., Ltd | +86-25-58227606 +86-15305155328 | China | 4128 | 58 | Inquiry |